Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

(2013) Antoinette Moran et al.   LANCET

Antibodies to watch in 2013

(2013) Janice M Reichert   mAbs

XoMA 052, a potential disease-modifying anti-interleukin-1 beta (IL-1 beta) regulatory antibody, shows reductions in hs-cRP, HbA1c and FPG after subcutaneous injection in a randomized, blinded, placebo-controlled trial in subjects with type 2 diabetes mellitus

(2012) J.D. Feldstein et al.   Canadian Journal of Diabetes

Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen

(2012) Paul M Ridker et al.   CIRCULATION

Dysregulated Toll-Like Receptor-Induced Interleukin-1  and Interleukin-6 Responses in Subjects at Risk for the Development of Type 1 Diabetes

(2012) A. K. Alkanani et al.   DIABETES

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

(2012) C. Cavelti-Weder et al.   DIABETES CARE

One Target—Two Different Binding Modes: Structural Insights into Gevokizumab and Canakinumab Interactions to Interleukin-1β

(2012) Michaela Blech et al.   JOURNAL OF MOLECULAR BIOLOGY

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study

(2011) Ahmet Gül et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis

(2011) Jelena Vojinovic et al.   ARTHRITIS AND RHEUMATISM

Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade: Evidence of Improved Immune Regulation

(2011) V. Ablamunits et al.   DIABETES

Treatment with Anakinra Improves Disposition Index But Not Insulin Sensitivity in Nondiabetic Subjects with the Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

(2011) Edwin J. P. van Asseldonk et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases

(2011) Alexander M. Owyang et al.   mAbs

Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes

(2011) Kathryn M. Sumpter et al.   PEDIATRIC DIABETES

Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus

(2010) Douglas O. Sobel et al.   ACTA DIABETOLOGICA

Anti-inflammatory Agents: Present and Future

(2010) Charles A. Dinarello   CELL

Short-term IL-1β blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes

(2010) Srinath Sanda et al.   CLINICAL IMMUNOLOGY

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

(2010) B. Keymeulen et al.   DIABETOLOGIA

XOMA 052, an Anti-IL-1β Monoclonal Antibody, Improves Glucose Control and β-Cell Function in the Diet-Induced Obesity Mouse Model

(2010) Alexander M. Owyang et al.   ENDOCRINOLOGY

Prediction and Pathogenesis in Type 1 Diabetes

(2010) Anette-G. Ziegler et al.   IMMUNITY

Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity

(2010) Marina K. Roell et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

(2010) Seth L Masters et al.   NATURE IMMUNOLOGY

Blockade of interleukin 1 in type 1 diabetes mellitus

(2010) Thomas Mandrup-Poulsen et al.   Nature Reviews Endocrinology

Cytokine production by islets in health and diabetes: cellular origin, regulation and function

(2010) Marc Y. Donath et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

An Essential Role for the NLRP3 Inflammasome in Host Defense against the Human Fungal Pathogen Candida albicans

(2009) Amy G. Hise et al.   Cell Host & Microbe

Sensing pathogens and danger signals by the inflammasome

(2009) Joao HF Pedra et al.   CURRENT OPINION IN IMMUNOLOGY

Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

(2009) C. M. Larsen et al.   DIABETES CARE

Glucose Promotes the Production of Interleukine-1β and Cyclooxygenase-2 in Mesangial Cells via Enhanced (Pro)Renin Receptor Expression

(2009) Jiqian Huang et al.   ENDOCRINOLOGY

Pro-interleukin (IL)-1β Shares a Core Region of Stability as Compared with Mature IL-1β While Maintaining a Distinctly Different Configurational Landscape

(2009) Kendra L. Hailey et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

(2009) Helen J. Lachmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes

(2009) Jeffrey C Barrett et al.   NATURE GENETICS

Increased Secretion and Expression of Myostatin in Skeletal Muscle From Extremely Obese Women

(2008) D. S. Hittel et al.   DIABETES

Minutes of The 43rd General Assembly of The European Association for The Study of Diabetes

(2008)   DIABETOLOGIA

An update on preventive and regenerative therapies in diabetes mellitus

(2008) M. Reimann et al.   PHARMACOLOGY & THERAPEUTICS